The innate immune sensor NLRC3 attenuates Toll-like receptor signaling via modification of the signaling adaptor TRAF6 and transcription factor NF-κB
Sensors of the NLR family generally activate innate immunity. Ting et al ., however, demonstrate that the little-known NLRC3 negatively regulates Toll-like receptor signaling by altering ubiquitination of the signaling adaptor TRAF6. Several members of the NLR family of sensors activate innate immun...
Saved in:
Published in | Nature immunology Vol. 13; no. 9; pp. 823 - 831 |
---|---|
Main Authors | , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
New York
Nature Publishing Group US
01.09.2012
Nature Publishing Group |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Sensors of the NLR family generally activate innate immunity. Ting
et al
., however, demonstrate that the little-known NLRC3 negatively regulates Toll-like receptor signaling by altering ubiquitination of the signaling adaptor TRAF6.
Several members of the NLR family of sensors activate innate immunity. In contrast, we found here that NLRC3 inhibited Toll-like receptor (TLR)-dependent activation of the transcription factor NF-κB by interacting with the TLR signaling adaptor TRAF6 to attenuate Lys63 (K63)-linked ubiquitination of TRAF6 and activation of NF-κB. We used bioinformatics to predict interactions between NLR and TRAF proteins, including interactions of TRAF with NLRC3.
In vivo
, macrophage expression of
Nlrc3
mRNA was diminished by the administration of lipopolysaccharide (LPS) but was restored when cellular activation subsided. To assess biologic relevance, we generated
Nlrc3
−/−
mice. LPS-treated
Nlrc3
−/−
macrophages had more K63-ubiquitinated TRAF6, nuclear NF-κB and proinflammatory cytokines. Finally, LPS-treated
Nlrc3
−/−
mice had more signs of inflammation. Thus, signaling via NLRC3 and TLR constitutes a negative feedback loop. Furthermore, prevalent NLR-TRAF interactions suggest the formation of a 'TRAFasome' complex. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Article-2 ObjectType-Feature-1 Present addresses: Department of Biology, Franklin and Marshall College, Lancaster, Pennsylvania, USA (B.K.D.); Duke Translational Research Institute, Duke University, Durham, North Carolina, USA (E.K.H.); HIV Drug Discovery Unit, Infectious Diseases Medicines Discovery & Development, GlaxoSmithKline, Research Triangle Park, North Carolina, USA (Z.Y.); Department of Medicine, Division of Liver Diseases, Mount Sinai School of Medicine, New York, New York, USA (A.H.R.); and Department of Biochemistry and Molecular Biology, Oregon Health & Science University, Portland, Oregon, USA (B.J.C.). |
ISSN: | 1529-2908 1529-2916 |
DOI: | 10.1038/ni.2378 |